secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950103-24-016317
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission
-----------------------------------------------------------------------------

- Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).
- Completed pre-BLA meeting with FDA; full alignment on BLA content for PRGN-2012 in RRP; rolling submission planned Q4 2024.
- Commercial and manufacturing readiness underway for potential 2025 launch of PRGN-2012.
- Confirmatory trial for PRGN-2012 initiated; end of Phase 1b meeting for PRGN-3006 in AML expected early 2025.
- August 2024 equity offering raised net $30.9M; workforce reduced by over 20%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/0000950103-24-016317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324016317/dp220702_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-016317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer